&Partners’s Cumberland Pharmaceuticals CPIX Stock Holding History

&Partners’s Portfolio CPIX Stock Details CPIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-11,000	Closed	-$36.9K	–	2135
2025 Q2	$36.9K	Hold	11,000	–	–	﹤0.01%	1956
2025 Q1	$48.5K	Buy	+11,000	New	+$45.6K	﹤0.01%	1735
2024 Q1	–	Sell	-11,000	Closed	-$19.7K	–	494
2023 Q4	$19.7K	Buy	+11,000	New	+$20.2K	﹤0.01%	293

Other funds holding CPIX

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

&Partners's CPIX Position: Q3 2025 in Review

&Partners sold out of Cumberland Pharmaceuticals (CPIX) in Q3 2025, closing a stake of 11,000 shares — an estimated $36.9K sold.

&Partners first reported a position in CPIX in Q4 2023 and held it in 3 quarters. The position peaked at $48.5K in Q1 2025. 30 funds tracked by Wall St. Rank hold CPIX as of Q3 2025.

&Partners reported no remaining Cumberland Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
&Partners sold 11,000 Cumberland Pharmaceuticals shares in Q3 2025, an estimated $36.9K.
&Partners first reported a position in Cumberland Pharmaceuticals in Q4 2023 and held it in 3 quarters.
&Partners's Cumberland Pharmaceuticals position peaked at $48.5K in Q1 2025.
30 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q3 2025.

Based on &Partners's 13F filing for Q3 2025, filed 14 Nov 2025.